RaySearch Laboratories AB (CHIX:RAYBS) 3-Year RORE % : 29.27% (As of Mar. 2026)


CHIX:RAYBS RaySearch Laboratories AB CHIX:RAYBS
93 GF Score
Price kr234.70
GF Value kr181.24
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is RaySearch Laboratories AB 3-Year RORE %?

RaySearch Laboratories AB CHIX:RAYBS 93 3-Year RORE % is 29.27 as of Mar. 2026. GuruFocus rates CHIX:RAYBS with a GF Score™ of 93/100 and a GF Value™ of kr181.24 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 604 Healthcare Providers & Services companies, RaySearch Laboratories AB ranks better than 76.16% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. RaySearch Laboratories AB's 3-Year RORE % for the quarter that ended in Mar. 2026 was 29.27%.

The industry rank for RaySearch Laboratories AB's 3-Year RORE % or its related term are showing as below:

CHIX:RAYBs's 3-Year RORE % is ranked better than
76.16% of 604 companies
in the Healthcare Providers & Services industry
Industry Median: 0.195 vs CHIX:RAYBs: 29.27

RaySearch Laboratories AB  (CHIX:RAYBs) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


RaySearch Laboratories AB 3-Year RORE % Related Terms


RaySearch Laboratories AB 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for RaySearch Laboratories AB's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaySearch Laboratories AB 3-Year RORE % Chart

RaySearch Laboratories AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,676.47 -97.92 223.81 63.33 37.92

RaySearch Laboratories AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.73 52.10 46.85 37.92 29.27

CHIX:RAYBS vs VEEV, BTSG, TEM: 3-Year RORE % Comparison

For the Health Information Services subindustry, RaySearch Laboratories AB's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RaySearch Laboratories AB 3-Year RORE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where RaySearch Laboratories AB's 3-Year RORE % falls into.


CHIX:RAYBS
93GF Score
RaySearch Laboratories AB CHIX:RAYBS
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaySearch Laboratories AB 3-Year RORE % Calculation

RaySearch Laboratories AB's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 6.54-2.94 )/( 16-3.7 )
=3.6/12.3
=29.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 29.27 mean?
RaySearch Laboratories AB (CHIX:RAYBS) has a 3-Year RORE % of 29.27 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on RaySearch Laboratories AB and its competitors. According to the industry distribution chart, RaySearch Laboratories AB ranks #144 out of 604 companies in the Healthcare Providers & Services industry, placing it in the top 23.8%.
Is RaySearch Laboratories AB's 3-Year RORE % too high?
RaySearch Laboratories AB's current 3-Year RORE % is 29.27. The Healthcare Providers & Services industry median 3-Year RORE % is 0.20. RaySearch Laboratories AB's value of 29.27 is 14910.3% above this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #144 out of 604 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, RaySearch Laboratories AB has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's 3-Year RORE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #144 out of 604 companies for 3-Year RORE %. This places RaySearch Laboratories AB in the top 24% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 0.20. RaySearch Laboratories AB's value of 29.27 is 14910.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.20, based on 604 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current 3-Year RORE % of 29.27 is 14910.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current 3-Year RORE % is 29.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (CHIX:RAYBS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr181.24, compared to a current price of kr234.70 — trading 29.5% above its estimated fair value. The current 3-Year RORE % is 29.27 and 14910.3% above the Healthcare Providers & Services industry median of 0.20. RaySearch Laboratories AB's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For RaySearch Laboratories AB (CHIX:RAYBS), the current 3-Year RORE % is 29.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaySearch Laboratories AB (CHIX:RAYBS) Overvalued in 2026?

Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued. The current stock price of kr234.70 is trading 29.5% above its estimated GF Value™ of kr181.24. GuruFocus considers RaySearch Laboratories AB to be Modestly Overvalued.

Key valuation signals for CHIX:RAYBS:

  • 3-Year RORE %: 29.27
  • GF Value™: kr181.24 vs. price of kr234.70 (29.5% above fair value)
  • GF Score™: 93/100 with 2 warning signs
  • Industry Position: 14910.3% above the Healthcare Providers & Services median (#144 of 604)

No single metric tells the full story. See the CHIX:RAYBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RaySearch Laboratories AB Business Description

Address Eugeniavagen 18C, Stockholm, SWE, 113 68
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
93GF Score

Get the complete analysis for CHIX:RAYBS

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr234.70
Price
kr181.24
GF Value